Abstract 1002
Background
Orego is an anti-CA 125 cancer vaccine whereas nivo is a programmed death-1 inhibitor. Both agents are clinically active in advanced EOC. We hypothesize that their combination will elicit a systemic CA 125-specific T cell response which is synergistic, safe and clinically efficacious in rEOC patients (pts).
Methods
Pts with rEOC, fallopian tube or primary peritoneal carcinoma who have received ≥2 prior chemotherapy lines were recruited in this phase Ib/IIa study. Study objectives were to characterize the safety and tolerability of orego + nivo, and determine the recommended dose for expansion (RDE)/recommended phase II dose (RP2D) of this combination. Using a modified 3 + 3 design, pts were treated starting at orego 2mg Q4W (dose level 1) + nivo 240mg Q2W. 2 lower doses of orego were specified in case of dose-limiting toxicities (DLT). A minimum of 6 and maximum of 18 pts would be accrued for dose finding. Additional 14 pts will be treated at RP2D in the dose expansion cohort.
Results
6 pts with median age 61 years (range 52.0 – 63.0) and ECOG performance status 1 were treated at dose level 1. All had EOC (4 high grade serous, 2 clear cell) and a median of 4 (range 3 – 9) treatment lines before study entry. No DLT were observed. Treatment-related adverse events (AE) included grade 1 events of arthralgia, rash, transaminitis, fatigue, and anorexia. 2/6 (33.3%) pts experienced grade 1-2 thyroid-related immune-related AE. 5 serious adverse events (SAE) were observed but they were deemed unlikely/not related to study treatment, including 2 episodes of grade 4 sepsis in 1 pt who eventually died of progressive disease (PD). Dose delay of orego and nivo occurred in 1 pt because of hospitalization for fever (SAE) followed by scheduling reasons. Dose omissions of nivo occurred in 2 pts due to grade 4 sepsis in 1 pt, and grade 1 thyroiditis in another. Analysis of exploratory immune correlate(s) is underway and will be reported at the meeting.
Conclusions
Orego 2mg Q4W with nivo 240mg Q2W was selected as the RDE/RP2D to treat rEOC. Further evaluation of safety and efficacy of this novel combination is ongoing in our dose expansion cohort.
Clinical trial identification
NCT03100006.
Legal entity responsible for the study
National Cancer Centre Singapore.
Funding
OncoQuest Inc.
Editorial Acknowledgement
Disclosure
J.J. Chan: Advisory role: Eisai, Pfizer; Travel, Accommodations, Expenses: Synthon, Novartis, Pfizer. T.J.Y. Tan: Advisory role: Novartis, Pfizer; Research funding: Bayer, Novartis; Travel, Accommodations, Expenses: Merck Sharp & Dohme, Eisai, Pfizer. J.W.K. Chia: Honoraria: AstraZeneca; Consulting or Advisory role: Tessa Therapeutics, Biomark, Aslan Pharmaceuticals, MSD, AstraZeneca, Roche; Research funding: Bayer, Bristol Myers Squibbs; Travel, Accommodations, Expenses: AstraZeneca, Bristol Myers Squibbs. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract